[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-384043-105":59,"doc-detail-384043-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rechallenge-with-anti-pd-1-inhibitors-in-patients-with-recurrent-gynecologic-malignancies","Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies","","Retrospective analysis evaluated treatment outcomes of immune checkpoint inhibitor (ICI) rechallenge using PD-1 inhibitors in 20 patients with recurrent gynecologic cancers across two tertiary centers from January 2018 to September 2022. Median age was 56 years, with cervical, vulvar, ovarian, and endometrial cancers represented. Initial responses showed limited CR/PR rates with median progression-free survival (PFS) of 2.8 months, while second-treatment responses included CR, PR, and stable disease. Median PFS on rechallenge was 1.8 months and median overall survival reached 21.3 months; AE-related discontinuations did not show AE relapse during the second ICI course.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rechallenge-with-anti-pd-1-inhibitors-in-patients-with-recurrent-gynecologic-malignancies/384043/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rechallenge-with-anti-pd-1-inhibitors-in-patients-with-recurrent-gynecologic-malignancies/384043.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this study?","Question",{"text":112,"@type":113},"The study investigates treatment outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with recurrent gynecologic cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted?",{"text":117,"@type":113},"Medical records of 20 patients treated with PD-1 inhibitor rechallenge for recurrent gynecologic cancers were retrospectively reviewed at two tertiary centers between January 2018 and September 2022.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings for responses and survival?",{"text":121,"@type":113},"Initial ICI treatment showed a complete response (CR) and partial response (PR) in some patients, with median PFS of 2.8 months. During second ICI treatment, CR, PR, and stable disease were observed; median PFS to the second ICI was 1.8 months and median overall survival was 21.3 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},384043,1790817167,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original Article  \nYonsei Med J 2023 Oct;64(10):587-592 [https://doi.org/10.3349/ymj.2023.0063](https://doi.org/10.3349/ymj.2023.0063)  \npISSN: 0513-5796 · eISSN: 1976-2437  \n\n| Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies\u003Cbr>Migang Kim1*, Chi-Son Chang2*, Min Chul Choi1, Jeong-Won Lee2, Hyun Park1, and Won Duk Joo1 1Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam; 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. |\n| --- |\n| Purpose: We investigated the treatment outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with recurrent gynecologic cancers.\u003Cbr>Materials and Methods: We retrospectively reviewed the medical records of 20 patients who underwent rechallenge with PD-1 inhibitors for recurrent gynecologic cancers at two tertiary centers between January 2018 and September 2022.\u003Cbr>Results: The median age of the patients was 56 years (range, 35–79). Seven (35%), 1 (5%), 11 (55%), and 1 (5%) patients presented with cervical, vulvar, ovarian, and endometrial cancers, respectively. Sixteen (80%) patients received pembrolizumab and 4 (20%) received nivolumab at first treatment. Eight (40%) and 12 (60%) patients received pembrolizumab and nivolumab, respectively, at second treatment. At initial ICI treatment, 1 (5%) and 4 (20%) cases of a complete response (CR) and a partial response (PR) were observed, respectively, with a median progression-free survival (PFS) of 2.8 months (range, 1.4–49.6). Reasons for first ICI discontinuation were disease progression (n=16), severe adverse events (AEs) (n=2), and treatment withdrawal (n=2). During second ICI treatment, 1 (5%) patient achieved CR, 2 (10%) showed PR, and 5 (25%) experienced stable disease. The median PFS to second ICI was 1.8 months (range, 0.4–10.4). The median overall survival was 21.3 months (range, 10.1–52.7). Neither patient who discontinued ICI treatment due toAEs experienced AE relapse during second ICI treatment.\u003Cbr>Conclusion: These results suggest that responses to ICI rechallenge are not as intolerable as responses to previous ICI. Clinicians should carefully consider rechallenge with PD-1 inhibitors outside of clinical trials until there are sufficient data to routinely support this practice.\u003Cbr>KeyWords: Gynecologic malignancy, immune checkpoint inhibitor, recurrence, rechallenge |\n\nINTRODUCTION  \nThe introduction of immune checkpoint inhibitors (ICIs) over Received: March 30, 2023 Revised: June 30, 2023  \nAccepted: July 26, 2023 Published online: September 13, 2023  \nCo-corresponding authors: Min Chul Choi, MD, Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea.  \nE-mail: [oursk79@cha.ac.kr](oursk79@cha.ac.kr) and  \nJeong-Won Lee, MD, PhD, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.  \nE-mail: [garden.lee@samsung.com](garden.lee@samsung.com)  \n*Migang Kim and Chi-Son Chang contributed equally to this work.  \n•The authors have no potential conflicts of interest to disclose.  \n© Copyright: Yonsei University College of Medicine 2023  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/](https://creativecommons.org/licenses/)[ ](https://creativecommons.org/licenses/)[by-nc/4.0](by-nc/4.0)) [which](which) permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nthe last decade represents a major advancement in the treatment of many types of solid tumors and has enabled sustained recovery and possible tumor remission in limited numbers of patients.1 Patients exposed to ICIs have incre","cbCaiiE2SRJyWhpB","https://ap.wps.com/l/cbCaiiE2SRJyWhpB","pdf",298135,"English","# Purpose\n# Materials and Methods\n# Results\n# Conclusion\n# KeyWords","[{\"question\":\"What is the purpose of this study?\",\"answer\":\"The study investigates treatment outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with recurrent gynecologic cancers.\"},{\"question\":\"How was the study conducted?\",\"answer\":\"Medical records of 20 patients treated with PD-1 inhibitor rechallenge for recurrent gynecologic cancers were retrospectively reviewed at two tertiary centers between January 2018 and September 2022.\"},{\"question\":\"What were the key findings for responses and survival?\",\"answer\":\"Initial ICI treatment showed a complete response (CR) and partial response (PR) in some patients, with median PFS of 2.8 months. During second ICI treatment, CR, PR, and stable disease were observed; median PFS to the second ICI was 1.8 months and median overall survival was 21.3 months.\"}]","Rechallenge with Anti-PD-1 Inhibitors in Patients with Recurrent Gynecologic Malignancies | PDF",1790260973,15]